An oral anti-CTGF compound PBI-4050 (ProMetic Life Sciences Inc.), has been shown to reduce fibrosis in multiple organs and reduce hepatocellular carcinoma in animals (http://www.prometic.com/en/therapeutics/scientific-library.php). This evidence concerns the gene CCN2 and hepatocellular carcinoma.